Company Description

BOKO Therapeutics Inc., founded in March 2022, is an immuno-oncology company based on pioneering work from MD Anderson. BOKO focuses on developing novel cancer therapeutics for solid tumors. The company believes its novel approach to empowering patients' innate and adaptive immune responses against cancer will play a leading role in the successful treatment of solid tumors. The company initially focuses on oncogene-driven solid tumors of unmet need, including lung, pancreatic, and CRC cancers.